• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·CBPL.BO
Share

Chandra Bhagat Pharma Ltd Stocks

₹ 33.22Last Updated 28.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₹ 2.50M

₹ 33.22
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Chandra Bhagat Pharma Ltd. specializes in the distribution and commercialization of a diverse array of pharmaceutical, critical care, and general healthcare solutions. Their extensive product lineup encompasses various pharmaceutical formulations, notably intravenous (IV) and intramuscular (IM) injectable medications, alongside select tablet forms, serving both national and international clientele. Furthermore, the company actively promotes and markets active pharmaceutical ingredients (APIs). Their offerings are designed to address a spectrum of conditions, including rheumatoid and osteo-arthritis, osteoporosis, carpal tunnel syndrome, tendonitis, rotator cuff tears, muscular dystrophy, myasthenia gravis, and lupus erythematosus, among other health issues. Established in 1944 by Chandravadan C. Bhagat, the company's main operations are based in Mumbai, India.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 12:36

A tanker carrying cargo for a Chevron subsidiary was attacked by drones in the Black Sea

30.07.2026 11:58

Samsung's chip business profits have surged 255-fold. Why are its shares soaring?

30.07.2026 10:50

Top Stories This Morning: U.S. Strikes Iran, AI Helps Samsung, EU to Tighten Oversight of ChatGPT

30.07.2026 09:00

Airbus's profits exceeded expectations amid an increase in aircraft deliveries

30.07.2026 08:00

Citi recommended buying Ford shares following the earnings report. Why does the bank expect them to rise by 33%?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026